Zacks Investment Research downgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS) from a buy rating to a hold rating in a research report sent to investors on Thursday, November 9th.
According to Zacks, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. “
A number of other analysts have also recently commented on the stock. Stifel Nicolaus boosted their price target on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a hold rating in a research report on Wednesday, August 9th. Needham & Company LLC reiterated a buy rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday, July 26th. BMO Capital Markets boosted their target price on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an outperform rating in a report on Wednesday, November 8th. Evercore ISI initiated coverage on shares of Ionis Pharmaceuticals in a report on Wednesday, August 16th. They issued an outperform rating and a $65.00 target price on the stock. Finally, Laidlaw restated a buy rating and issued a $65.00 price objective on shares of Ionis Pharmaceuticals in a report on Monday, August 14th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. Ionis Pharmaceuticals presently has a consensus rating of Hold and an average target price of $50.31.
In other news, SVP Patrick R. O’neil sold 1,000 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. Following the completion of the transaction, the senior vice president now owns 10,633 shares in the company, valued at approximately $584,815. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO B Lynne Parshall sold 16,118 shares of the stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $65.00, for a total transaction of $1,047,670.00. Following the completion of the transaction, the chief operating officer now owns 33,526 shares of the company’s stock, valued at approximately $2,179,190. The disclosure for this sale can be found here. In the last quarter, insiders have sold 110,886 shares of company stock valued at $6,391,045. 2.13% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC purchased a new position in Ionis Pharmaceuticals during the 3rd quarter valued at about $100,000. GSA Capital Partners LLP grew its holdings in shares of Ionis Pharmaceuticals by 10.9% during the third quarter. GSA Capital Partners LLP now owns 23,893 shares of the company’s stock worth $1,211,000 after buying an additional 2,348 shares in the last quarter. Iguana Healthcare Management LLC purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth about $761,000. Parallel Advisors LLC grew its holdings in shares of Ionis Pharmaceuticals by 60.3% during the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock worth $182,000 after buying an additional 1,250 shares in the last quarter. Finally, California Public Employees Retirement System grew its holdings in shares of Ionis Pharmaceuticals by 1.6% during the third quarter. California Public Employees Retirement System now owns 222,900 shares of the company’s stock worth $11,301,000 after buying an additional 3,600 shares in the last quarter. Hedge funds and other institutional investors own 91.58% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/zacks-investment-research-downgrades-ionis-pharmaceuticals-inc-ions-to-hold/1771664.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.